ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 945-955

  Hurdman, J ^a   Condliffe, R ^a,c   Elliot, C A ^a,c   Davies, C ^a   Hill, C ^a   Wild, J M ^b,c   Capener, D ^b   Sephton, P ^a   Hamilton, N ^a   Armstrong, I J ^a   Billings, C ^a   Lawrie, A ^b,c   Sabroe, I ^a,b,c   Akil, M ^a   O'Toole, L ^a   Kiely, D G ^a,c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c National Institute for Health Research Cardiovascular Biomedical Research Unit ^*  (United Kingdom)

Author keywords

Congenital heart disease; Pulmonary hypertension; Registry; Survival; Systemic sclerosis; Thromboembolism

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE REGISTRY; ENDARTERECTOMY; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS HYPOVENTILATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SLEEP DISORDER; SURVIVAL RATE; SURVIVAL TIME; SYNDROME DELINEATION; SYSTEMIC SCLEROSIS;

ADULT; AGED; DIAGNOSIS-RELATED GROUPS; ENDARTERECTOMY; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERRAL AND CONSULTATION; REGISTRIES; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 84860326397     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00078411     Document Type: Article

References (51)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
2. Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial metaanalyses. Eur Heart J 2010; 31: 2080-2086.
3. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1122-1127. (Pubitemid 351717571)
4. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999; 160: 523-528. (Pubitemid 29380667)
5. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on themanagement of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63: Suppl. 2, ii1-ii41.
6. NHS National Specialised Commissioning Group. Interim Commissioning Policy. Target Therapies for the Treatment of Pulmonary Arterial Hypertension in Adults. National Health Service, 2009. Available from www.emscg.nhs.uk/library/ P009V1NationalSpecialisedCommissioningGroupPolicy2.pdf.
7. National Audit of Pulmonary Hypertension 2010. First annual report: key findings from the National Audit of Pulmonary Hypertension for the United Kingdom, Channel Islands and Isle of Man. Report for the audit period April 2009 to March 2010. Document ref: IC05010111. Leeds, National Health Service Information Centre for Health and Social Care, 2010. Available from www.ic.nhs.uk/webfiles/NCASP/Heart%20Disease/NHS-IC-PH-Audit-INTERACTIVE-18-01- 11.pdf.
8. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019-1024. (Pubitemid 23011018)
9. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
10. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95: 199-203. (Pubitemid 40092084)
11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223. (Pubitemid 17137857)
12. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079-1087.
13. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
14. Cottin V, Le Pavec J, Prévot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-111.
15. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
16. Paulus WJ. Novel strategies in diastolic heart failure. Heart 2010; 96: 1147-1153.
17. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-1393.
18. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
19. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34: 1005-1011.
20. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-36.
21. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58: 1803-1809. (Pubitemid 351847535)
22. Haest I, Kiely DG, Needham L, et al. North Derbyshire, South Yorkshire and Bassetlaw Commissioning Consortium (NORCOM) Policy on Pulmonary Hypertension. Sheffield, Sheffield Public Health Network, 2004. Available from www.doncasterpct.nhs.uk/documents/Appendix2.pdf.
23. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111. (Pubitemid 40847788)
25. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
26. Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009; 34: 132-137.
27. Vonk Noordegraaf A, Naeije R. Right ventricular function in scleroderma-related pulmonary hypertension. Rheumatology (Oxford) 2008; 47: Suppl. 5, v42-v43.
28. Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-379.
29. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
30. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110. (Pubitemid 351194756)
31. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
32. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
33. Peacock AJ, Murphy NF, McMurray JV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109. (Pubitemid 47074013)
34. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050. (Pubitemid 44497786)
35. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350. (Pubitemid 36269414)
36. Tanaka E, Harigai M, Tanaka M, et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-287. (Pubitemid 34118774)
37. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17: 1292-1298. (Pubitemid 20382853)
38. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531. (Pubitemid 351294886)
39. Dawson JK, Goodson NG, Graham DR, et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000; 39: 1320-1325. (Pubitemid 32045857)
40. Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. Chest 1981; 79: 105-107. (Pubitemid 11167408)
41. Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86: 299-315. (Pubitemid 47415009)
42. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
43. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993.
44. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001; 119: 818-823. (Pubitemid 32197654)
45. Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: 151-158.
46. World Health Organization Global Health Observatory Database. HIV/AIDS: Data on the size of the epidemic: Number of people (all ages) living with HIV. http://apps.who.int/ghodata/ Date last accessed: February 16, 2011.
47. Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4: 257-265.
48. Fischler M, Speich R, Dorschner L, et al. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly 2008; 138: 371-378. (Pubitemid 351969706)
49. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
50. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
51. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.